gabapentin has been researched along with MS (Multiple Sclerosis) in 29 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 9.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 9.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 7.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)." | 7.70 | An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998) |
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy." | 7.70 | Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998) |
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 5.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 5.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 3.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
"A 40-year-old patient with acquired horizontal and vertical nystagmus and severe oscillopsia secondary to multiple sclerosis had combined treatment with gabapentin and a vertical Kestenbaum-type procedure." | 3.71 | Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. ( Constantinescu, CS; Gottlob, I; Jain, S; Proudlock, F, 2002) |
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)." | 3.70 | An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998) |
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy." | 3.70 | Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998) |
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
"Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
"Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
"The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
"Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
"Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations." | 1.56 | Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020) |
"Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
"Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis." | 1.37 | Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011) |
"Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
"Acquired Pendular Nystagmus (APN) may cause distressing visual symptoms in patients who are already suffering a severe general disease." | 1.31 | Improvement of acquired pendular nystagmus by gabapentin: case report. ( Fabre, K; Smet-Dieleman, H; Zeyen, T, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (24.14) | 18.2507 |
2000's | 12 (41.38) | 29.6817 |
2010's | 9 (31.03) | 24.3611 |
2020's | 1 (3.45) | 2.80 |
Authors | Studies |
---|---|
Bobenko, AI | 1 |
Heller, S | 1 |
Schmitt, N | 1 |
Cherdtrakulkiat, R | 1 |
Lawung, R | 1 |
Nabu, S | 1 |
Tantimavanich, S | 1 |
Sinthupoom, N | 1 |
Prachayasittikul, S | 1 |
Prachayasittikul, V | 1 |
Zhang, B | 1 |
Wu, C | 1 |
Zhang, Z | 2 |
Yan, K | 1 |
Li, C | 2 |
Li, Y | 4 |
Li, L | 3 |
Zheng, C | 1 |
Xiao, Y | 1 |
He, D | 1 |
Zhao, F | 1 |
Su, JF | 1 |
Lun, SM | 1 |
Hou, YJ | 1 |
Duan, LJ | 1 |
Wang, NC | 1 |
Shen, FF | 1 |
Zhang, YW | 1 |
Gao, ZW | 1 |
Li, J | 5 |
Du, XJ | 1 |
Zhou, FY | 1 |
Yin, Z | 1 |
Zhu, J | 2 |
Yan, D | 1 |
Lou, H | 1 |
Yu, H | 1 |
Feng, C | 1 |
Wang, Z | 1 |
Wang, Y | 4 |
Hu, X | 1 |
Li, Z | 2 |
Shen, Y | 1 |
Hu, D | 1 |
Chen, H | 1 |
Wu, X | 1 |
Duan, Y | 1 |
Zhi, D | 1 |
Zou, M | 2 |
Zhao, Z | 1 |
Zhang, X | 2 |
Yang, X | 2 |
Zhang, J | 2 |
Wang, H | 1 |
Popović, KJ | 1 |
Popović, DJ | 1 |
Miljković, D | 1 |
Lalošević, D | 1 |
Čapo, I | 1 |
Popović, JK | 1 |
Liu, M | 1 |
Song, H | 2 |
Xing, Z | 1 |
Lu, G | 1 |
Chen, D | 1 |
Valentini, AM | 1 |
Di Pinto, F | 1 |
Coletta, S | 1 |
Guerra, V | 1 |
Armentano, R | 1 |
Caruso, ML | 1 |
Gong, J | 1 |
Wang, N | 1 |
Bian, L | 1 |
Wang, M | 1 |
Ye, M | 1 |
Wen, N | 1 |
Fu, M | 1 |
Fan, W | 1 |
Meng, Y | 1 |
Dong, G | 1 |
Lin, XH | 1 |
Liu, HH | 1 |
Gao, DM | 1 |
Cui, JF | 1 |
Ren, ZG | 1 |
Chen, RX | 1 |
Önal, B | 1 |
Özen, D | 1 |
Demir, B | 1 |
Akkan, AG | 1 |
Özyazgan, S | 1 |
Payette, G | 1 |
Geoffroy, V | 1 |
Martineau, C | 1 |
Villemur, R | 1 |
Jameel, T | 1 |
Baig, M | 1 |
Gazzaz, ZJ | 1 |
Tashkandi, JM | 1 |
Al Alhareth, NS | 1 |
Khan, SA | 1 |
Butt, NS | 1 |
Wang, J | 2 |
Geng, Y | 1 |
Zhang, Y | 3 |
Wang, X | 2 |
Liu, J | 2 |
Basit, A | 1 |
Miao, T | 1 |
Liu, W | 1 |
Jiang, W | 1 |
Yu, ZY | 1 |
Wu, L | 2 |
Qu, B | 1 |
Sun, JX | 1 |
Cai, AL | 1 |
Xie, LM | 1 |
Groeneveld, J | 1 |
Ho, SL | 1 |
Mackensen, A | 1 |
Mohtadi, M | 1 |
Laepple, T | 1 |
Genovesi, S | 1 |
Nava, E | 1 |
Bartolucci, C | 1 |
Severi, S | 1 |
Vincenti, A | 1 |
Contaldo, G | 1 |
Bigatti, G | 1 |
Ciurlino, D | 1 |
Bertoli, SV | 1 |
Slovak, JE | 1 |
Hwang, JK | 1 |
Rivera, SM | 1 |
Villarino, NF | 1 |
Li, S | 1 |
Cao, G | 1 |
Ling, M | 1 |
Ji, J | 1 |
Zhao, D | 1 |
Sha, Y | 1 |
Gao, X | 1 |
Liang, C | 2 |
Guo, Q | 1 |
Zhou, C | 1 |
Ma, Z | 1 |
Xu, J | 1 |
Wang, C | 1 |
Zhao, W | 1 |
Xia, X | 1 |
Jiang, Y | 1 |
Peng, J | 1 |
Jia, Z | 1 |
Li, F | 1 |
Chen, X | 2 |
Mo, J | 1 |
Zhang, S | 2 |
Li, X | 1 |
Huang, T | 1 |
Zhu, Q | 1 |
Wang, S | 1 |
Ge, RS | 1 |
Fortunato, G | 1 |
Lin, J | 2 |
Agarwal, PK | 1 |
Kohen, A | 1 |
Singh, P | 1 |
Cheatum, CM | 1 |
Zhu, D | 1 |
Hayman, A | 1 |
Kebede, B | 1 |
Stewart, I | 1 |
Chen, G | 1 |
Frew, R | 1 |
Guo, X | 1 |
Gong, Q | 1 |
Borowiec, J | 1 |
Han, S | 1 |
Zhang, M | 1 |
Willis, M | 1 |
Kreouzis, T | 1 |
Yu, K | 1 |
Chirvony, VS | 1 |
Sekerbayev, KS | 1 |
Pérez-Del-Rey, D | 1 |
Martínez-Pastor, JP | 1 |
Palazon, F | 1 |
Boix, PP | 1 |
Taurbayev, TI | 1 |
Sessolo, M | 1 |
Bolink, HJ | 1 |
Lu, M | 1 |
Lan, Y | 1 |
Xiao, J | 1 |
Song, M | 1 |
Chen, C | 1 |
Huang, Q | 1 |
Cao, Y | 1 |
Ho, CT | 1 |
Qi, B | 1 |
Wang, Q | 1 |
Zhang, W | 1 |
Fang, L | 1 |
Xie, CL | 1 |
Chen, R | 1 |
Yang, S | 1 |
Xia, JM | 1 |
Zhang, GY | 1 |
Chen, CH | 1 |
Yang, XW | 1 |
Domenech-Ximenos, B | 1 |
Garza, MS | 1 |
Prat-González, S | 1 |
Sepúlveda-Martínez, Á | 1 |
Crispi, F | 1 |
Perea, RJ | 1 |
Garcia-Alvarez, A | 1 |
Sitges, M | 1 |
Kalumpha, M | 1 |
Guyo, U | 1 |
Zinyama, NP | 1 |
Vakira, FM | 1 |
Nyamunda, BC | 1 |
Varga, M | 1 |
Drácz, L | 1 |
Kolbenheyer, E | 1 |
Varga, F | 1 |
Patai, ÁV | 1 |
Solymosi, N | 1 |
Patai, Á | 1 |
Kiss, J | 1 |
Gaál, V | 1 |
Nyul, Z | 1 |
Mosdósi, B | 1 |
Valdez, M | 1 |
Moosavi, L | 1 |
Heidari, A | 1 |
Novakovic-Agopian, T | 1 |
Kornblith, E | 1 |
Abrams, G | 1 |
McQuaid, JR | 1 |
Posecion, L | 1 |
Burciaga, J | 1 |
D'Esposito, M | 1 |
Chen, AJW | 1 |
Samy El Gendy, NM | 1 |
Wesolowska, P | 1 |
Georg, D | 1 |
Lechner, W | 1 |
Kazantsev, P | 1 |
Bokulic, T | 1 |
Tedgren, AC | 1 |
Adolfsson, E | 1 |
Campos, AM | 1 |
Alves, VGL | 1 |
Suming, L | 1 |
Hao, W | 1 |
Ekendahl, D | 1 |
Koniarova, I | 1 |
Bulski, W | 1 |
Chelminski, K | 1 |
Samper, JLA | 1 |
Vinatha, SP | 1 |
Rakshit, S | 1 |
Siri, S | 1 |
Tomsejm, M | 1 |
Tenhunen, M | 1 |
Povall, J | 1 |
Kry, SF | 1 |
Followill, DS | 1 |
Thwaites, DI | 1 |
Izewska, J | 1 |
Kang, JH | 1 |
Yoon, Y | 1 |
Song, J | 1 |
Van de Winckel, A | 1 |
Gauthier, L | 1 |
Chao, CT | 1 |
Lee, YH | 1 |
Li, CM | 1 |
Han, DS | 1 |
Huang, JW | 1 |
Huang, KC | 1 |
Ni, L | 1 |
Güttinger, R | 1 |
Triana, CA | 1 |
Spingler, B | 1 |
Baldridge, KK | 1 |
Patzke, GR | 1 |
Shen, X | 1 |
Wang, B | 1 |
Xie, S | 1 |
Deng, W | 1 |
Wu, D | 1 |
Zhang, Q | 1 |
Voskamp, BJ | 1 |
Peelen, MJCS | 1 |
Ravelli, ACJ | 1 |
van der Lee, R | 1 |
Mol, BWJ | 1 |
Pajkrt, E | 1 |
Ganzevoort, W | 1 |
Kazemier, BM | 1 |
Tibrewala, R | 1 |
Bahroos, E | 1 |
Mehrabian, H | 1 |
Foreman, SC | 1 |
Link, TM | 1 |
Pedoia, V | 1 |
Majumdar, S | 1 |
Jablonski, CL | 1 |
Leonard, C | 1 |
Salo, P | 1 |
Krawetz, RJ | 1 |
Yoon, N | 1 |
Hong, SN | 1 |
Cho, JG | 1 |
Jeong, HK | 1 |
Lee, KH | 1 |
Park, HW | 1 |
Barman, S | 1 |
Konai, MM | 1 |
Samaddar, S | 1 |
Haldar, J | 1 |
Mohamed, HSH | 1 |
Li, CF | 1 |
Hu, ZY | 1 |
Deng, Z | 1 |
Chen, LH | 1 |
Su, BL | 1 |
Chu, K | 1 |
Liu, YP | 1 |
Li, YB | 1 |
Zhang, H | 1 |
Xu, C | 1 |
Zou, Z | 1 |
Wu, Z | 1 |
Xia, Y | 1 |
Zhao, P | 1 |
Wang, HT | 1 |
de Biase, S | 1 |
Pellitteri, G | 1 |
Gigli, GL | 1 |
Valente, M | 1 |
Comi, G | 2 |
Solari, A | 1 |
Leocani, L | 1 |
Centonze, D | 1 |
Otero-Romero, S | 2 |
Redon, S | 1 |
Graillon, N | 1 |
Régis, J | 1 |
Donnet, A | 1 |
Khan, N | 1 |
Woodruff, TM | 1 |
Smith, MT | 1 |
Trojano, M | 1 |
Sastre-Garriga, J | 1 |
Hartung, HP | 1 |
Soelberg Sørensen, P | 1 |
Thompson, AJ | 1 |
Vermersch, P | 1 |
Gold, R | 1 |
Montalban, X | 1 |
Starck, M | 1 |
Albrecht, H | 1 |
Pöllmann, W | 1 |
Dieterich, M | 1 |
Straube, A | 1 |
Bittner, S | 1 |
Höhn, K | 1 |
Göbel, K | 1 |
Kleinschnitz, C | 1 |
Wiendl, H | 1 |
Meuth, SG | 1 |
Shaikh, AG | 1 |
Thurtell, MJ | 1 |
Optican, LM | 1 |
Leigh, RJ | 2 |
Heinzlef, O | 1 |
Monteil-Roch, I | 1 |
Jain, S | 1 |
Proudlock, F | 1 |
Constantinescu, CS | 1 |
Gottlob, I | 3 |
Fabre, K | 1 |
Smet-Dieleman, H | 1 |
Zeyen, T | 1 |
Yetimalar, Y | 1 |
Gürgör, N | 1 |
Başoğlu, M | 1 |
Hsu, C | 1 |
Sliwa, JA | 1 |
Sarrigiannis, P | 1 |
Tsakanicas, C | 1 |
Anagnostouli, M | 1 |
Karandreas, N | 1 |
Solaro, C | 5 |
Brichetto, G | 1 |
Battaglia, MA | 1 |
Messmer Uccelli, M | 2 |
Mancardi, GL | 5 |
Shery, T | 1 |
Proudlock, FA | 1 |
Sarvananthan, N | 2 |
McLean, RJ | 1 |
Choudhuri, I | 1 |
Mueller, ME | 1 |
Gruenthal, M | 1 |
Olson, WL | 1 |
Olson, WH | 1 |
Samkoff, LM | 1 |
Daras, M | 1 |
Tuchman, AJ | 1 |
Koppel, BS | 1 |
Houtchens, MK | 1 |
Richert, JR | 1 |
Sami, A | 1 |
Rose, JW | 1 |
Lunardi, GL | 1 |
Capello, E | 1 |
Inglese, M | 1 |
Uccelli, A | 2 |
Khan, OA | 1 |
Uccelli, MM | 2 |
Cutter, NC | 1 |
Scott, DD | 1 |
Johnson, JC | 1 |
Whiteneck, G | 1 |
Guglieri, P | 1 |
Bandini, F | 1 |
Castello, E | 1 |
Mazzella, L | 1 |
Stahl, JS | 1 |
Rottach, KG | 1 |
Averbuch-Heller, L | 1 |
von Maydell, RD | 1 |
Collins, SD | 1 |
Schapiro, RT | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
5 reviews available for gabapentin and MS (Multiple Sclerosis)
Article | Year |
---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
7 trials available for gabapentin and MS (Multiple Sclerosis)
Article | Year |
---|---|
Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.
Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose | 2010 |
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2004 |
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid | 1997 |
Open label gabapentin treatment for pain in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab | 1997 |
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C | 2000 |
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Electrooculography; Female; Gabapentin; gamma- | 2001 |
17 other studies available for gabapentin and MS (Multiple Sclerosis)
Article | Year |
---|---|
Italian consensus on treatment of spasticity in multiple sclerosis.
Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections | 2020 |
First Bite Syndrome After Trigeminal Radiosurgery: Case Report and Pathophysiology.
Topics: Adult; Carbamazepine; Cheek; Combined Modality Therapy; Drug Therapy, Combination; Facial Muscles; F | 2018 |
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli | 2014 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli | 2016 |
Pharmacological tests of hypotheses for acquired pendular nystagmus.
Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A | 2011 |
Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis.
Topics: Acetates; Adult; Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diplopia; Excitator | 2002 |
Improvement of acquired pendular nystagmus by gabapentin: case report.
Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2001 |
Phantom breast pain as a source of functional loss.
Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si | 2004 |
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study.
Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography; | 2004 |
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 2005 |
The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab | 2006 |
Survey of management of acquired nystagmus in the United Kingdom.
Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists; | 2007 |
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1997 |
An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 1998 |
Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1998 |
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis | 1999 |
A pilot study of gabapentin as treatment for acquired nystagmus.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Stem; Cerebrovascular Disorders; Cyclohexanecarboxyl | 1996 |